📊 XLO Key Takeaways
Is Xilio Therapeutics, Inc. (XLO) a Good Investment?
Xilio demonstrates exceptional revenue growth (+590% YoY) and maintains a strong cash position ($137.5M) with zero debt, indicating successful early commercialization. However, severe operating losses (-$42M) with -95.9% operating margins and negative operating cash flow (-$5M quarterly) reveal unsustainable unit economics that must improve significantly to justify continued investment.
Why Buy Xilio Therapeutics, Inc. Stock? XLO Key Strengths
- Extraordinary revenue growth of 589.9% YoY suggests successful product commercialization and market traction
- Strong cash position of $137.5M with zero debt provides 5-7 year runway to achieve profitability
- Favorable balance sheet with 2.58x current ratio and positive equity cushion of $35.3M
XLO Stock Risks: Xilio Therapeutics, Inc. Investment Risks
- Operating losses of $42M on $43.8M revenue represent -95.9% operating margin, indicating fundamental profitability challenges
- Negative operating cash flow of -$5M per quarter demonstrates cash burn despite revenue growth, unsustainable long-term
- Pharmaceutical sector risks including regulatory delays, clinical trial failures, market adoption uncertainty, and competitive threats
Key Metrics to Watch
- Path to operating profitability and gross margin expansion as revenue scales
- Operating cash flow trend and cash burn rate relative to revenue growth rate
- Cash runway depletion timeline and need for capital raise or profitability inflection
Xilio Therapeutics, Inc. (XLO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.58x current ratio provides a solid financial cushion.
XLO Profit Margin, ROE & Profitability Analysis
XLO vs Healthcare Sector: How Xilio Therapeutics, Inc. Compares
How Xilio Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Xilio Therapeutics, Inc. Stock Overvalued? XLO Valuation Analysis 2026
Based on fundamental analysis, Xilio Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Xilio Therapeutics, Inc. Balance Sheet: XLO Debt, Cash & Liquidity
XLO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Xilio Therapeutics, Inc.'s revenue has grown significantly by 590% over the 5-year period, indicating strong business expansion. The most recent EPS of $-15.24 indicates the company is currently unprofitable.
XLO Revenue Growth, EPS Growth & YoY Performance
XLO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.3M | -$14.0M | $-0.11 |
| Q2 2025 | $2.4M | -$13.9M | $-0.16 |
| Q1 2025 | $2.9M | -$13.3M | $-0.18 |
| Q3 2024 | $2.3M | -$14.0M | $-0.22 |
| Q2 2024 | $2.4M | -$13.9M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Xilio Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
XLO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Xilio Therapeutics, Inc. (CIK: 0001840233)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XLO
What is the AI rating for XLO?
Xilio Therapeutics, Inc. (XLO) has an AI rating of HOLD with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XLO's key strengths?
Claude: Extraordinary revenue growth of 589.9% YoY suggests successful product commercialization and market traction. Strong cash position of $137.5M with zero debt provides 5-7 year runway to achieve profitability.
What are the risks of investing in XLO?
Claude: Operating losses of $42M on $43.8M revenue represent -95.9% operating margin, indicating fundamental profitability challenges. Negative operating cash flow of -$5M per quarter demonstrates cash burn despite revenue growth, unsustainable long-term.
What is XLO's revenue and growth?
Xilio Therapeutics, Inc. reported revenue of $43.8M.
Does XLO pay dividends?
Xilio Therapeutics, Inc. does not currently pay dividends.
Where can I find XLO SEC filings?
Official SEC filings for Xilio Therapeutics, Inc. (CIK: 0001840233) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XLO's EPS?
Xilio Therapeutics, Inc. has a diluted EPS of $-4.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XLO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Xilio Therapeutics, Inc. has a HOLD rating with 65% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XLO stock overvalued or undervalued?
Valuation metrics for XLO: ROE of -99.3% (sector avg: 15%), net margin of -80.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XLO stock in 2026?
Our dual AI analysis gives Xilio Therapeutics, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XLO's free cash flow?
Xilio Therapeutics, Inc.'s operating cash flow is $-5.0M, with capital expenditures of $518.0K. FCF margin is -12.6%.
How does XLO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -80.1% (avg: 12%), ROE -99.3% (avg: 15%), current ratio 2.58 (avg: 2).